Dr. Zibelman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
333 Cottman Ave
Philadelphia, PA 19111Phone+1 215-728-2500Fax+1 215-728-3639
Education & Training
- Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
- University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 2007 - 2011
- Lewis Katz School of Medicine at Temple UniversityClass of 1997
Certifications & Licensure
- PA State Medical License 2012 - 2024
- IL State Medical License 2007 - 2014
- WI State Medical License 2011 - 2013
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 102 citationsImmune‐Related Adverse Events as a Biomarker in Non‐Melanoma Patients Treated with Programmed Cell Death 1 InhibitorsJulia Judd, Matthew Zibelman, Elizabeth Handorf, John O'Neill, Chethan Ramamurthy
The Oncologist. 2017-10-01 - 20 citationsOrteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).Neeraj Agarwal, Catherine M Tangen, Maha H A Hussain, Shilpa Gupta, Melissa Plets
Journal of Clinical Oncology. 2022-10-01 - 102 citationsAdjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomise...Sumanta Kumar Pal, Robert Uzzo, Jose Antonio Karam, Viraj A Master, Frede Donskov
Lancet. 2022-10-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: